论文部分内容阅读
Objective: The third generation epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)osimertinib(OSI,also known as AZD9291)has been approved for treatment of EGFR T790M positive mutation NSCLC patients who have progressed after gefitinib or erlotinib treatment.Whether or not OSI can be used as the first option for NSCLC patients with naive EGFR sensitive mutation was controversial.